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Introduction
The incidence of complete Achilles tendon rupture is 18 per 100 000 patient-years1 and is usually
diagnosed clinically by GPs. The extent of clinical misdiagnosis is unknown in Norway, but may be
high.2 This is important as delayed treatment has unfavourable consequences.1,3 We report how a
GP, with no clinical ultrasound experience, recorded images with a pocket-sized ultrasound device
(PSUD) under supervision to confirm a complete Achilles tendon rupture. This could present a new
indication for GP ultrasound.
Case report
A 36-year-old man experienced acute pain above the right heel accompanied by an audible snap
while sprinting. He immediately had difficulty walking and 3 hours later consulted an on-call GP. Pos-
terior ankle swelling with a tender depression 3 cm proximal to the calcaneum was found. Active
plantar flexion against resistance was weak and Simmonds–Thompson test was ‘partially positive’ on
applying a strong calf-squeeze. Based on these findings, calf muscle rupture was diagnosed as the
Achilles tendon was thought to be intact. The patient was advised to elevate the foot and wait 2
weeks for improvement. Two days later a second GP, who was aware of a history of an audible snap,
considered complete tendon rupture and reexamined the patient. Findings included an absent right
heel raise due to weakness, minimal active plantar flexion against gravity and lying prone, significant
right ankle swelling without bruising, and an altered angle of declination. Palpation elicited no ankle
bony tenderness, yet a painful gap was identified 6 cm proximal from the calcaneal attachment,
along the line of the Achilles tendon. Simmonds–Thompson’s test was clearly positive. The positive
Simmond’s triad indicated a clinical diagnosis of complete rupture of the Achilles tendon.
A 3.4–8 MHz linear array probe PSUD (VScan dual probe, GE Healthcare), set at a depth of
3.5 cm, was used under the supervision of a rheumatologist experienced in ultrasound. The tendon
was enlarged from 1 cm to 6 cm above the calcaneal insertion, where a clear gap was seen
(Figure 1). Two hours later a radiologist-performed ultrasound (LOGIQ E9, GE Healthcare)
and reported an enlarged distal tendon and a complete rupture at 5–6 cm from the calcaneal attach-
ment, creating a 2.7 cm blood-filled gap (Figure 2). Surgical exploration 8 days post-injury found a
complete Achilles tendon rupture ‘5–10 cm above the ankle joint’.
Discussion
Tromsø Hospital serves a large area with a population of approximately 160 000. Between 2010–
2014 an average of 21 patients per year were referred by their GP for suspected Achilles rupture.
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Introduction
Last summer our small medical team visit the Calais ’Jungle’. Since that time muc has hanged
and the camp is being demolished and by the time this article is read, it will probably be long gone.
Some you gsters are finally being brought to the UK under the ’Dubs’ amendment. H wever, once
this camp is clear d it will not solve the ongoing flight of refugees from war torn areas: other camps
are already appearing.
July 2016
A young Afghan man caught his finger on a sharp point while trying to cross a barbed wire fence.
The finger was partially degloved. He attended the local hospital, where they placed a few sutures,
but now, 2 weeks later, the skin is necrotic and the underlying tissue looks infected. He is in danger
of losing his finger.
A middle-aged Sudanese man has been having rigors and is generally unwell. He says it is similar
to when he last had malaria.
A young Ukrainian woman complains of lower back pain and urinary frequency.
Th paths of these three people may never have crossed; yet here they are, denizens of the Calais
Jungle. They turn up to a makeshift primary care ‘clinic’ that we set up in the heart of the unofficial
refugee camp on weekend in July 2016.
With only basic medical supplies, we are immediately ch llenged by what we see. How can w
arrange sec dary care for the young Afghan in danger of losing his finger? We try to persuade him
to return to the original local hospital, but is reluctant. It was not a good experience for him t
first time round.
With the other two patients, it is easier. They can attend the Salam clinic run by a loc l association
during w ekdays. Later, we receive word that malaria has been confirmed in our Su anese patient.
More people arrive, presenting with scabies, rat bites, tinea, chest infections, and wheezing from
inhaling smok from fires lit to cook keep warm in their t nts t night. We examin a severely
malnourish d 2-year-old boy. We meet everal of the ca ’s 600 unaccompanied children, at grave
risk of sexual exploitation. We learn that there i inadequate safeguarding in place to prot ct them.
A young Eritrean man comes i worried about his eye. H has sustained direct ocular trauma from a
rubber bullet, and will never see normally again out of that eye. We see aematomas from olice
batons, and hear about children being exposed to tear gas again and again (Figure 1).
The reality
These ar no ordinary patients. They h ve travelled far from home to escape war, poverty, and mis-
ery. They have ndured personal odysseys to get here, experienced untold hardships, and suffered
unimaginable privations. Many have survived the loss of their families, torture, and rape. Their jour-
neys over, for the moment at least, they must make their homes in the Calais Jungle. Their new shel-
ters are in many cases mere tarpaulin covers, and their new beds just rugs on the ground. They own
next to nothing. Ther is little for them to do, besides use their ingenuity to cross the English Chan-
nel in search of a better life. They are vuln rabl to xploitation, crime, injury, and disease. Poten-
tially violent clashes with local police, with other ethnic groups resident in the Jungle, or local far
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Abstract
Background: Antidepress nt use has increased exponentially in recent decades, mostly due to long
continuation.
Aim: To assess the effectiven ss f a tailored rec mm ndatio to withdraw antidepr ssant
treatment.
Design & setting: Randomised controlled trial in primary care (PANDA study) in the Netherlands.
Method: Long-term antidepressant users (9 months) were selected from GPs prescription
databases. Patients were diagnosed with the Composite International Diagnostic Interview (CIDI).
Long-term users without indication for maintenance treatment (overtreatment) were selected. The
intervention consisted of disclosure of the current psychiatric diagnosis combined with a tailored
treatment recommendation. Patients were followed for 12 months.
Results: The study included 146 participants from 45 family practices. Of the 70 patients in the
intervention group, 34 (49%) did not comply with the advice to stop their antidepressant
medication. Of the 36 (51%) patients who agreed to try, only 4 (6%) succeeded. These figures were
consistent with the control group, where 6 (8%) of the 76 patients discontinued antidepressant use
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successfully. Patients who were recommended to discontinue their antidepressant medication
reported a higher relapse rate than the control group (26% versus 13%, P = 0.05).
Conclusion: Changing inappropriate long-term antidepressant use is difficult.
How this fits in
Antidepressant use has increased, largely due to long-term prescriptions. Antidepressants are not
very effective, especially in patients with depression of moderate severity.
GPs are sometimes reluctant to withdraw inappropriate long-term antidepressant medication and
long-term antidepressant users are frequently not motivated to stop antidepressant use.
Introduction
During the 1990s, antidepressants were promoted widely and GPs were criticised for underdiagnos-
ing and undertreating depressive and anxiety disorders.1–3 Efforts were made to increase quality of
care, and prescription rates for antidepressants increased.4
Now, contrary concerns are raised concerning overtreatment with antidepressants.5 Long-term
continuation contributes to the high level of antidepressant use.6–10 Studies suggest that many long-
term users are exposed to antidepressants unnecessarily.8,11,12 One-third of long-term antidepres-
sant users have been found to have no identifiable justification.12 In addition, a lack of medication
review during the continuation of antidepressant treatment has been highlighted.8 Clinical guide-
lines recommend limiting the duration of antidepressants to 6 months after remission for a first or
second depressive episode or a successfully treated anxiety disorder.13–16 The guidelines state that
if after 4–6 weeks no remission has occurred, the medication should be switched to another antide-
pressant; if after another period of 4–6 weeks no remission has occurred, the guidelines advocate
referral to a psychiatrist.13–16
Overtreatment with antidepressants is problematic. The effectiveness is questionable: about five
of every six antidepressant users do not benefit.17 From the GP perspective, it is important to dis-
cuss how patients can use their own resources to cope with their problems; providing medication
might be counterproductive, as medication use may disincentivise a patient to find non-pharmaco-
logical solutions, thereby diminishing patient empowerment in a context where regaining control is
essential for recovery.18
This study concludes that overtreatment with antidepressants is very prevalent and that a consid-
erable proportion of long-term use has no clinical justification. As such, this study aims to reduce
inappropriate long-term antidepressant use in general practice. The authors will evaluate the effec-
tiveness of a recommendation to cease antidepressant treatment which is tailored to both the
patient and the psychiatric diagnosis.
Method
Study design
The authors conducted a cluster randomised controlled trial in primary care.19 The original protocol
consisted of an overtreatment and an undertreatment trial. This article reports on the overtreatment
trial. A summary can be found at the Nederlands Trial Register (NTR2032) (http://www.trialregister.
nl/trialreg/admin/rctview.asp?TC=2032).
Selection of study subjects
The study was conducted in 45 general practices in the Netherlands between February 2010 and
March 2013. GPs identified long-term antidepressant users in their prescription database. GPs
excluded patients based on the exclusion criteria below.
Eveleigh R et al. BJGP Open ; DOI: 10.3399/bjgpopen17X101265 2 of 11
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Inclusion and exclusion criteria
Inclusion criteria
1. Long-term antidepressant use (9 months). All antidepressants were included, except mono-
amine oxidase inhibitors.
2. Written informed consent.
Exclusion criteria
1. Current treatment in a psychiatric inpatient or outpatient clinic.
2. Appropriate use of long-term antidepressants according to the Dutch guidelines for depres-
sive and anxiety disorders (that is, a history of recurrent depression [3 episodes] and/or a
recurrent psychiatric disorder with at least two relapses after antidepressant discontinuation).
3. History of psychosis, bipolar disorder, or obsessive compulsive disorder.
4. Current diagnosis of substance use disorder, excluding tobacco, because of the necessity of
specialised treatment.
5. Non-psychiatric indication for long-term antidepressant usage, for example neuropathic pain.
6. Hearing impairment and/or insufficient understanding of the Dutch language.
Age was not an exclusion criterion.
Informed consent procedure
Patients received an information brochure, via their GP, stating the purpose of the study; namely, to
improve the treatment of patients using antidepressants long-term and to give a patient-tailored
treatment recommendation. Patients could consent by filling out a return slip. Consenting patients
were contacted in order to check inclusion and exclusion criteria.
Diagnostic procedures and trial allocation
Eligible patients underwent a structured psychiatric interview by telephone using the CIDI (version
3.0), conducted by trained interviewers.20–23 Patients without a current psychiatric diagnosis or
another indication for continued use (for example, neuropathic pain or chronic pain) were allocated
to the trial.
Randomisation
To prevent contamination between intervention and control group, a cluster randomisation was per-
formed with the general practice as the unit of clustering. Random assignment was executed after
patient recruitment was concluded per practice; a practice was either an intervention practice or a
control practice.
Follow-up procedures
Over the course of a year, all patients were routinely followed up. After 1 year they underwent the
CIDI again. The self-report questionnaire was repeated every 3 months during this year.
Intervention
A patient-specific letter was sent to the GP with the recommendation to discontinue the antidepres-
sant. Information was provided on antidepressant tapering and the discontinuation syndrome. A
gradual tapering programme was recommeded.19 The GP invited the patient to discuss the recom-
mendation. No treatment restrictions were imposed in case of a relapse or the onset of a new psy-
chiatric disorder after discontinuation. A return slip was included, to ascertain the patient’s intention
to comply with the recommendation. When either the GP or the patient did not intend to comply,
the reasons for this were requested. In the control group, GPs were unaware which patients partici-
pated in this study and continued usual care.
Primary outcome
The primary outcome was the proportion of participants who successfully discontinued their long-
term antidepressant use after 1 year. Successful discontinuation is defined as no antidepressant use
during the preceding 6 months and the absence of a depressive or anxiety disorder during the 1-
year follow-up, as assessed by the CIDI. All information about medication use was collected in the
Eveleigh R et al. BJGP Open ; DOI: 10.3399/bjgpopen17X101265 3 of 11
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follow-up CIDI, as well as in self-report questionnaires. Missing and contradicting prescriptions were
checked by contacting the GP.
Secondary outcome
The severity of general distress and depressive symptoms was assessed by the Brief Symptom Inven-
tory (BSI-53),24 and the Centre for Epidemiological Studies Depression Scale (CESD),25 at baseline
and after 3, 6, 9 and 12 months’ follow-up. Somatic comorbidity was assessed with the TiC-P
questionnaire.26
Sample size estimation
The prospective sample size estimation aimed to provide at least 85% power for two-tailed testing
with a type-1 error rate of 5%. To account for the cluster-randomisation, an intraclass correlation of
0.05 was used. Assumptions with respect to recruitment and outcomes were difficult to estimate. A
20% discontinuation rate for the control and 50% for the intervention group was expected. Sponta-
neous non-adherence to antidepressants is found to be 25%,27 and it was expected that this rate
would decline as treatment time elapsed. The expected discontinuation rate in the intervention
group was based on a primary care benzodiazepines discontinuation study.28–29 An average Dutch
general practice (2400 patients) has approximately 50–60 patients using antidepressants long-
term,30 with one-third possibly doing so inappropriately.8 This study’s recruitment rate was based
on the results of three GPs piloting patient recruitment in their practices. It was found that an aver-
age practice would be able to recruit three patients who fulfilled all of the inclusion criteria and none
of the exclusion criteria. Assuming a dropout rate of 25%, the required sample size was calculated
as 34 practices and 136 patients.
Statistical analyses
Analyses were conducted in IBM SPSS Statistics (version 20). Outcome analyses were performed on
an intention-to-treat basis. Patients with an unknown primary outcome were conservatively classified
as not having discontinued the antidepressant medication. The secondary outcome measures were
analysed using a mixed models procedure for repeated measures, thus accounting for any missing
values.
Results
Forty-five practices participated. In total, 6442 long-term antidepressant users were identified, of
whom 2411 (37%) were deemed eligible by their GP. Of these patients, 358 (15%) consented to par-
ticipate and 146 were included in this study (Figure 1).
Study population
Patient characteristics were well balanced at randomisation; any differences were not statistically sig-
nificant (Table 1). Figure 2 shows the distribution of patients and their outcomes.
In the intervention practices, the recommendation to discontinue was rejected in almost half of
the cases (n = 34/70, 49%; 95% confidence interval [CI] = 37 to 60): by the patient in 14 cases (41%),
the GP in 1 (3%), and as a shared decision in 16 (47%); in three cases data were missing. Reasons for
rejecting the recommendation were as follows: fear of recurrence (n = 19, 56%); relapse after previ-
ous discontinuation (n = 4, 12%); presence of psychological symptoms (n = 5, 15%); wanting a sec-
ond opinion (n = 4, 12%); and other, unspecified reasons (n = 2, 6%).
General distress or depressive symptoms at 3 months (approximately the time of consultation
with GP to discuss the given recommendation) were not predictive for acceptance of the recommen-
dation to discontinue (mean BSI 0.4, 95% CI = 0.2 to 0.5; mean CESD 17, 95% CI = 13 to 21 versus
mean BSI 0.4, 95% CI = 0.2 to 0.6; mean CESD 15, 95% CI = 11 to 18).
Primary outcome
In the intervention group, four patients (6%, 95% CI = 2 to 14) successfully discontinued their antide-
pressant use, in comparison to six patients (8%, 95% CI = 4 to 16) in the control group. When
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Figure 1. Flow diagram of practices and participants.
Figure 1 continued on next page
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combining the intervention and control groups, successful discontinuation of antidepressant use was
found in 10 patients (7%, 95% CI = 4 to 12).
Secondary outcomes
The study found a marginally significant higher relapse rate in the intervention group (n = 18/70;
26%) compared to the control group (n = 10/76; 13%) (P = 0.05). Comparison of patients who con-
tinued their antidepressants identified a non-statistically significant higher relapse rate in the inter-
vention versus control group (25% versus 11%, P = 0.07). This difference was not associated with
antidepressant discontinuation.
Figure 1 continued
aPost-randomisation patients did not meet inclusion criteria (human error during inclusion process). bPatients who did not complete follow-up
interview. cPatients excluded with unknown primary outcome (due to dual primary outcome, excluded cases are less than patients lost to follow-up; that
is, antidepressant use known via GP prescription database). dIntervention group restricted to patients with the intention to comply to recommendation
and patients excluded with unknown primary outcome.
Table 1. Baseline characteristics of participants (inappropriate long-term antidepressant users) in the
overtreatment trial at individual level in frequencies, unless stated otherwise. Overtreatment: 9 months
antidepressant use, without a current indication for maintenance therapy
Overtreatment trial, n (%)
Control (n = 76) Intervention (n = 70)
Mean age, years (SD) 56 (14.3) 56 (12.9)
Male 24 (32) 20 (29)
Marital status
Married or living together 60 (79) 56 (80)
Separated or divorced 0 (0) 2 (3)
Widow/widower 7 (9) 2 (3)
Single 9 (12) 9 (13)
Lifetime psychiatric diagnosis
Any lifetime psychiatric diagnosis 48 (63) 53 (76)
Depression 35 (46) 39 (56)
Panic disorder or agoraphobia 13 (17) 13 (19)
Generalised anxiety disorder 13 (17) 22 (31)
Social phobia 20 (26) 16 (23)
Antidepressant
Selective serotonin reuptake inhibitors 50 (66) 57 (81)
Serotonin–norepinephrine reuptake inhibitors 11 (14) 7 (10)
Other (non-tricyclic antidepressant drug) 10 (13) 2 (3)
Tricyclic antidepressant drugs 5 (7) 4 (6)
Median duration of antidepressant use at inclusion, years (range) 9.5 (1–56) 8.0 (1– 48)
Comorbidity
Cardiovascular disease 7 (9) 9 (13)
Cancer 6 (8) 8 (11)
Chronic obstructive pulmonary disease/asthma 12 (16) 9 (13)
Diabetes mellitus 11 (14) 3 (4)
SD = standard deviation.
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Patients who successfully discontinued their antidepressant did not differ from the rest of the
study population in sex, age, type of antidepressant used (selective serotonin reuptake inhibitors, tri-
cyclic antidepressants or other) or psychiatric diagnosis. However, the mean duration of antidepres-
sant use appeared to trend toward a shorter duration in patients who successfully discontinued their




This study shows the difficulty of discontinuing inappropriate long-term antidepressant use. Irrespec-
tive of the condition patients were allocated to, only 10 of the 146 patients with inappropriate long-
term use of antidepressants (that is, use not recommended by clinical guidelines), were able to suc-
cessfully stop in the year of the study. Half of the patients in this study rejected the recommendation
to discontinue. Even when intending to comply, more than half (56%) ultimately did not. Interest-
ingly, the number of patients in the control group spontaneously discontinuing their antidepressant
was similar to the number of patients discontinuing their antidepressant in accordance with the
recommendation.
A higher relapse rate was found in the intervention group. Strikingly, this was not associated with
antidepressant discontinuation (Figure 2). Focusing on the use of the antidepressant could have
caused a higher risk of relapse; patients could have felt obliged to act on this recommendation
Figure 2. Patient flow and outcome in the overtreatment trial.
In the intervention group 20/70 patients were lost to follow-up (12 in the group of patients with no intention to comply and 8 in the group with the
intention to comply with the recommendation). In the control group 10/76 patients were lost to follow-up. AD = antidepressant.
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without an internal motivation, causing more anxiety about potential relapse and, consequently, a
higher risk of actual relapse. In addition, it is possible that feelings of failure could arise when reject-
ing the recommendation, again resulting in a higher risk of relapse.
Strengths and limitations
As far as the authors are aware, this is the first randomised controlled clinical trial focusing on long-
term antidepressant use in patients in remission.
The studied intervention was based on previous experiences with discontinuation of long-term
benzodiazepine use, where a stepped-care approach was found to be effective.31 A minimal inter-
vention, consisting of an advisory letter or a consultation to discuss discontinuation with the GP
proved effective to discontinue benzodiazepines.32 Apparently, the parallel with antidepressants
was made too easily, with patients and GPs being hesitant to discontinue.
Of the large number of long-term antidepressant users, only a small portion consented to partici-
pate in this study (<15%). Patient recruitment is a known problem, especially in mental health
research.33 However, despite the low response rate, the sample size to provide sufficient power for
the trial was reached by approaching more practices and patients than originally anticipated. Due to
privacy regulations, these long-term antidepressant users remain anonymous until giving consent.
Unfortunately, it is not known why patients decided not to participate. It is conceivable that patients
who were not willing to participate were more reluctant to change their antidepressant treatment.
This would make the study’s findings even more concerning as, in those circumstances, the chances
are that with a larger, more generalisable population, the percentage of patients successfully discon-
tinuing their antidepressant medication would even be lower. The recruitment success of patients
for participation in such an evidence-based intervention could illustrate the difference between per-
ceived self-interest (by the patient) and perceived patient interest (by researchers and practitioners).
Further studies about antidepressant discontinuation should therefore focus on patients who are
motivated for discontinuation.
Due to the pragmatic nature of this study, the intervention was not imposed on the patients and
their GPs. Noncompliance with the given recommendation was found in almost half of the cases.
Further qualitative research might be helpful to understand the barriers patients and GPs perceive in
discontinuing long-term antidepressant use in patients in remission, and to facilitate the construction
of a more effective intervention to reduce inappropriate long-term antidepressant use.
Comparison with the literature
This study showed that many patients reject a proposal to discontinue antidepressant use, that many
GPs agreed with the decision not to follow the advice to discontinue and that a large number of
patients (32/36) who agreed to follow the protocol failed to do so. Clearly, there is a large gap
between what guidelines recommend and what happens in daily practice. Although deviation from a
guideline may be consistent with good care, the scale of non-adherence raises another possibility;
namely, that apprehensiveness about change and difficulties with discontinuation is much more
important than was initially expected. This apprehensiveness about change was found in both
patients and GPs. Qualitative research has suggested that patients attribute their wellbeing to the
(continued) use of antidepressants. They are more afraid of stopping than of continuing, taking a
’better safe than sorry’ approach.34–35 They believe their condition to be chronic and requiring life-
long treatment, while feeling uncomfortable with this prospect.34–36 GPs also perceive barriers to
discontinuation, wishing ’not to disturb the "equilibrium" the patient experiences’, to ’follow the
path of least resistance’ and to ’let patients be’.36 GPs operate in a difficult environment: dealing
with guidelines, their own fears, patients’ opinions and fears, and the difficult process of discontinua-
tion. Adherence to guidelines is difficult. Attempts to discontinue antidepressant use — while very
desirable in the light of the huge prescription rates — become a complex task when taking all these
factors into account.37
Lately, guidelines have become more conservative in their recommendations concerning the pre-
scription of antidepressant medication. It is conceivable that the GPs in the PANDA study did not
agree with the recent guidelines. Alternatively, it may be that GPs had to get used to these new
insights, with guidelines having previously advocated for increased antidepressant prescription. The
prescribing behaviour of GPs is certainly an important topic: they should become more reluctant in
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prescribing, and should inform patients that the medication will only be necessary for a limited
period of time and can be discontinued after being in remission for a period of 6 months. Patients
discontinuing their antidepressant medication should also receive more information, guidance and
support than they receive at present. In addition to the issue of the difficulty of discontinuing inap-
propriate antidepressant medication, there are several other reasons justifying a reluctance to pre-
scribe antidepressant medication. Firstly, the evidence of the substantial placebo effect in patients
with depression is strong, with the exception of the more severe cases.38 Secondly, the availability
of psychological treatments suitable for primary care is growing. Important examples are problem-
solving treatment and behavioural activation; both treatments can be delivered by junior mental
health workers.39
Implications for practice
This study demonstrates the difficulty of correcting unnecessary (according to the guidelines) long-
term antidepressant use, fuelled by an apprehensiveness regarding change on the part of both
patient and GP. A recommendation to discontinue is not effective, and maybe even counterproduc-
tive. The authors advocate developing education programmes for GPs, including such topics as GPs’
attitudes towards discontinuation, appropriately motivating patients to discontinue antidepressant
use, and managing the process of discontinuation. Notwithstanding, it is felt that the first, and possi-
bly most important, step to prevent inappropriate long-term use of antidepressant medication in pri-
mary care is to be more restrictive in prescribing antidepressant medication in the first place and
make more use of alternative, non-pharmalogical treatments. It might be useful to forewarn patients
about the difficulty of discontinuing and to encourage using antidepressants only for a limited
period. Regular review could possibly prevent both overtreatment and undertreatment.
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